摘要
目前的慢性乙型肝炎治疗不理想。聚乙二醇干扰素α-2a治疗HBeAg（＋）慢乙肝试验结果显示功效明显优于拉米夫定，延长派罗欣治疗疗的程可提高疗效，病毒YMDD变异明显少于拉米夫定。阿德福韦治疗HBeAg（-）的慢乙肝试验显示疗效明显，长期给予阿德福韦治疗是有好处的，耐药出现晚，发生率明显低于拉米夫定，对拉米夫定产生YMDD变异者，阿德福韦仍可使HBVDNA抑制在400拷贝／mL以下．聚乙二醇干扰素α-2a治疗HBeAg（-）慢乙肝试验结果显示在停药1年后仍可维持疗效，是HBeAg阴性慢乙肝治疗的首选药物之一。
Current treatments for chronic hepatitis B are suboptimal. Results of clinical trail shows that peginterferon alfa-2a offers superior efficacy over lamivudine in the treatment of HBeAg （＋） chronic hepatitis B, long-term therapy with Peginterferon alfa-2a is necessary, YMDD mutations were detected in patients receiving Peginterferon alfa-2a less common than receiving lamivudine. Adefovir offers superior efficacy in the treatment of HBeAg （-） chronic hepatitis B, long-term therapy with adefovir is necessary, resistance appears later and was detected in patients receiving adefovir less common than receiving lamivudine. Treating the patients who have YMDD mutations with adefovir can still suppress of HBV DNA levels to less than 400 copies per milliliter. Peginterferon alfa-2a still shows efficacy until one year after treatment in HBeAg （-） chronic hepatitis B. Peginterferon alfa-2a should be one of the first choice in the treatment of HBeAg （-） chronic hepatitis B.
出处
《世界感染杂志》
2005年第5期428-431,共4页
World Journal of Infection
